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Abstract
Microtubule-stabilizing and -destabilizing proteins play a crucial role in regulating the dynamic
instability of microtubules during neuronal development and synaptic transmission. The
microtubule-destabilizing protein SCG10 is a neuron-specific protein implicated in neurite
outgrowth. The SCG10 protein is significantly reduced in mature neurons, suggesting that its
expression is developmentally regulated. In contrast, the microtubule-stabilizing protein tau is
expressed in mature neurons and its function is essential for the maintenance of neuronal polarity
and neuronal survival. Thus, the establishment and maintenance of neuronal polarity may down-
regulate the protein level/function of SCG10. In this report, we show that treatment of PC12 cells
and neuroblastoma cells with the microtubule-stabilizing drug Taxol induced a rapid degradation
of the SCG10 protein. Consistently, overexpression of tau protein in neuroblastoma cells also
induced a reduction in SCG10 protein levels. Calpain inhibitor MDL-28170, but not caspase
inhibitors, blocked a significant decrease in SCG10 protein levels. Collectively, these results
indicate that tau overexpression and Taxol treatment induced a calpain-dependent degradation of
the microtubule-destabilizing protein SCG10. The results provide evidence for the existence of an
intracellular mechanism involved in the regulation of SCG10 upon microtubule stabilization.
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Introduction
The elongation and rapid shortening of microtubules, a process referred to as dynamic
instability, is crucial during neuronal differentiation (Mitchison and Kirschner, 1984; Dent
and Gertler, 2003). This process responds to external cues that control and guide molecular
changes required for the establishment of domains necessary for neuronal function (Dent
and Gertler, 2003). Several proteins that affect microtubule’s dynamic instability during
neuronal differentiation have been identified (Dent and Gertler, 2003). Some of these
proteins, such as SCG10 and stathmin, destabilize microtubules whereas others like the
micro-tubule-associated protein tau promote microtubule stabilization (Riederer et al., 1997;
Buèe et al., 2000; Grenningloh et al., 2004). Several studies indicated that both microtubule-
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stabilizing and -destabilizing proteins are essential for neurite outgrowth and neuronal
function (Buèe et al., 2000; Grenningloh et al., 2004). However, it is still unknown whether
these functional diverse proteins can affect or regulate each other’s functions to coordinate
microtubule’s dynamic instability.
SCG10 is a neuronal-specific protein of the same gene family as stathmin (Grenningloh et
al., 2004). The level of SCG10 protein is elevated during development and reduced in
adults, suggesting that its expression is developmentally regulated. This protein is found to
associate with membrane rafts and Golgi (Lutjens et al., 2000; Maekawa et al., 2001).
Additionally, SCG10 is enriched in growth cones during neurite outgrowth (Lutjens et al.,
2000; Grenningloh et al., 2004). Analysis of purified SCG10 protein from brain protein
extract detected the presence of higher molecular weight SCG10 species (Antonsson et al.,
1998). Further studies demonstrated that this shift in molecular weight is due to
phosphorylation. In vitro studies have shown that protein kinases A (PKA) phosphorylates
SCG10 at Ser50 and Ser97, whereas mitogen-activated protein kinase (MAPK) does it at
Ser62 and Ser73 (Antonsson et al., 1998; Grenningloh et al., 2004). Furthermore, cyclin-
dependent kinases, such as CDK5, have been shown to phosphorylate SCG10 at Ser73
(Grenningloh et al., 2004). These phosphorylation events adversely affect the microtubule-
destabilizing activity of SCG10 protein (Antonsson et al., 1998; Grenningloh et al., 2004).
The microtubule-associated tau proteins are preferentially expressed in neurons (Buèe et al.,
2000). However, tau expression has been also detected in other cell types (Buèe et al.,
2000). Similarly to SCG10, the biological function of tau proteins is adversely affected by
phosphorylation (Buèe et al., 2000; Lee et al., 2001). Hyperphosphorylation of tau proteins
and its aberrant intracellular aggregation have been identified as a hallmark in a family of
neurodegenerative disorders, collectively known as tauopathies (Lee et al., 2001). The best
known and studied tauopathy is Alzheimer’s disease (AD). The pathological role of tau in
these disorders is underscored by the identification of mutations in the tau gene of kindred
afflicted by neurodegeneration (Lee et al., 2001). Most of the identified mutations interfered
with the ability of tau proteins to bind tubulin and stabilize micro-tubules (Buèe et al., 2000;
Lee et al., 2001). Based on these findings, a loss-of-function model has been suggested to
explain tau-induced neurodegeneration (Feinstein and Wilson, 2005). Consistently, a
tauopathy mouse model treated with low dosages of the microtubule-stabilizing drug Taxol
exhibited a restoration of fast axonal transport, increase axonal microtubules, and improved
motor impairments (Zhang et al., 2005). Additionally, Taxol protected primary neurons from
the toxic effect induced by β-amyloid peptides (Aβ1–42) and mitigated tau phosphorylation
(Michaelis et al., 2004). These results suggest that microtubule depolymerization due to
disruption of the biological function of tau may play a fundamental role in the molecular
mechanism underlying tau-induced neurodegeneration.
Regulation of the biological function of microtubule-stabilizing and -destabilizing proteins
may be inherently interconnected. Here, we showed that both Taxol treatment and tau
overexpression induced a drastic reduction in SCG10 protein level. Calpain inhibitor but not
proteasomal or caspase inhibitors blocked this reduction in SCG10 protein. Collectively,
these results suggest that microtubule stabilization triggers a signaling cascade that leads to
the activation of calpains and degradation of microtubule-destabilizing proteins.
Materials and methods
Materials
Antibodies used in this project are polyclonal antibodies WK S44 specific to human tau (aa
162–178; 1:500; generated by Dr. Yen’s laboratory; DeTure et al., 2002), SCG10-BR
(Antonsson et al., 1998), SCG10-GL (DiPaolo et al., 1997), anti-actin (C-11; Santa Cruz
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Biotechnology), and anti-cleaved caspase-3 (Asp175; Cell Signaling Technology).
Monoclonal antibodies used are anti-α-tubulin and anti-ubiquitin (P4D1) from Santa Cruz
Biotechnology. Secondary antibodies used in western blot analysis are peroxidase-
conjugated goat anti-rabbit (1:4000) or goat anti-mouse (1:2000) Ig antibodies (Chemicon,
Temecula, CA, USA).
Pharmacological agents used are described below. Taxol (Paclitaxel) and Nocodazole were
purchased from Sigma. All other drugs, including epoxomicin, MG132, calpain inhibitor III
(MDL-28170), caspase inhibitor I (Z-VAD-FMK), lactacystin, H-89 dihydrochloride,
roscovitine, MEK inhibitor (PD 98059), and JNK inhibitor II (SP600125) were purchased
from EMD Biosciences. The specific concentrations used are described in the text.
Culture and drug treatment of PC12 cells
Pheochromocytoma cells (PC12) were maintained in growth media [DMEM supplemented
with 7.5% fetal calf serum (FCS), 7.5% horse serum (HS), 3.5 g/L glucose, 3.7 g/L sodium
bicarbonate, pH 7.3, 10 μg/mL streptomycin, and 10 U/mL penicillin] at 37°C/5%CO2.
Cultured undifferentiated PC12 (5×106 cells/plate; five plates per treatment) were treated
with different concentrations of Taxol (dissolved in ethanol) for 24 h. As control, equal
volume of ethanol was added to culture PC12 cells for the same interval of time. When
indicated, PC12 cells were pre-treated with specific inhibitors, at the concentration specified
in the text, for 3 h before the addition of 10 μM Taxol to the medium. To induce
differentiation, 100 ng/mL of nerve growth factor (NGF) was added directly to PC12 cells
cultured in minimal medium [DMEM supplemented with 3.5 g/L glucose, 3.7 g/L sodium
bicarbonate, pH 7.3, 1% FCS, 1% HS, 10 μg/mL streptomycin, and 10 U/mL penicillin] at
37°C/5%CO2. PC12 cells were incubated in NGF containing media for three days prior to
Taxol (10 μM) treatment for 24 h NGF-differentiated PC12 cells (for 3 days) were pre-
treated with calpain inhibitor (MDL28170) for 3 h prior to the addition of Taxol (10 μM) to
the medium.
Neuroblastoma cells and tau overexpression
The Tet-off inducible system was used to generate stable transfectant (M1C) expressing
wild-type human tau (4R0N). M1C cells were derived from human neuroblastoma BE(2)-
M17D cell line and maintained in growth media [DMEM supplemented with 10% fetal
bovine serum (FBS), 4.5 g/L of glucose, 3.7 g/L sodium bicarbonate, pH 7.3, 0.3 g L-
glutamine, 400 μg/mL G418, 1 μg/mL puromycin, 2 μg/mL tetracycline (Tet), 100 μg/mL
zeocin, and 100 μg/mL hygromycin] at 37°C/5% CO2. The cells were seeded in 10 cm dish
at 2×106 cells per plate (60–70% confluence) a day before Tet-off induction. Tau expression
was induced by thoroughly washing the cells with DMEM (without Tet) and adding fresh
medium with different concentrations (1 ng/ml, 10 ng/ml, or 100 ng/ml) of Tet. Cells were
cultured in the indicated medium for seven days. Fresh medium was supplemented on the
third and fifth day. When indicated, M1C cells were pre-treated with calpain inhibitor
MDL28170 (10 μM) or proteasome inhibitor MG132 (1.0 μM or 10 μM) for 3 h before
incubation in reduced concentration of Tet (1 ng/mL) for 48 h.
Western blot analysis
After the indicated incubation time, PC12 and M1C cells were collected and centrifuged to
remove culture medium. The cell pellet was resuspended in 1 mL of lysis buffer [20 mM
Tris base, pH 7.4; 150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM PMSF; 5 mM sodium
pyrophosphate; 30 mM β-glycerophosphate; 30 mM sodium fluoride]. The resuspended
cells were passed ten times through a syringe with a 27G1/2″ needle. The cell lysate was
spun down at 18,000×g for 2 min. The supernatant was removed and the pellet resuspended
in lysis buffer (500 μL). Total protein concentration was estimated using the colorimetric
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Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). Recombinant BSA was used as a
standard.
For western blot analysis, samples of equal protein concentration (10 μg) were loaded on
12.5% sodium dodecyl sulfate-polyacrylamide gel (SDS–PAGE). Proteins resolved by gel
electrophoresis were transferred to nitrocellulose membrane (BioRad, Hercules, CA, USA),
which were then incubated in blocking solution [5% dry milk; 0.1% Tween 20 in 1× TBS]
for 1 h prior to overnight incubation with the indicated primary antibody. After washing
with 1× TBS containing 0.1% Tween 20, the membranes were incubated at room
temperature with peroxidase-conjugated goat anti-mouse or anti-rabbit secondary antibodies
and washed again. Immunoreacted proteins were visualized with enhanced
chemiluminescence system (ECL plus; Amersham Biosciences, Piscataway, NJ, USA) and
exposure to X-ray film. When indicated, membranes were re-probed after extensive washing
(3 h) and incubation in blocking solution. Quantitative analyses were carried out using
MCID Imaging analysis software. Films of two different exposure times (5 s and 20 s) per
antibody (i.e., anti-SCG10 and anti-tubulin) were scanned. Then, the scanned images were
use to determine the relative intensity of the signal detected creating squares of the same size
enclosing the protein bands. The relative intensity detected in both films was corrected using
the signal detected from anti-tubulin from the respective film. The ratio was the same in
both films. The numbers reported represent the mean of three independent experiments and
the error bar shows the standard error [σ/(√n)] per treatment.
Results
SCG10 protein level is reduced upon Taxol treatment
Treatment of PC12 cells with increasing concentrations of the microtubule-stabilizing drug
Taxol (0.1–10 μM) induced a steady decline in the level of SCG10 protein (Fig. 1A;
SCG10) after 24 h of incubation. Upon Taxol treatment, an SCG10 protein band of higher
molecular weight than those observed in control samples was detected, suggesting that post-
translational modification of SCG10 proteins may be induced upon Taxol treatment (Figs.
1A and C, arrow). Additionally, there is a protein band detected at approximately ~17 kDa
(Fig. 1A, asterisk). Because the SCG10 antibody SCG10-BR has been shown to cross-react
with stathmin, the specific SCG10 antibody SCG10-GL was also used (Fig. 2). The results
showed that this protein band is likely to be derived from SCG10 (Fig. 2). The quantification
of three representative samples from each treatment condition demonstrated that, in 24 h, the
total level of SCG10 protein was significantly (p<0.0001) reduced upon Taxol treatment
(Fig. 1B). These results suggest that Taxol-mediated microtubule stabilization induces rapid
degradation of the microtubule-destabilizing SCG10 protein in PC12 cells.
The observed reduction in SCG10 protein level could be related to the process of cell death
after Taxol treatment and not an intrinsic cellular response to microtubule stabilization. In
order to gain information that helps to discriminate between these two possibilities,
undifferentiated PC12 cells were treated with 10 μM Taxol and samples collected at
different intervals (Fig. 1C). Taxol treatment of PC12 cells induced a reduction in SCG10
protein level after 4 h of incubation (Fig. 1C, compare lanes 1–2 with lanes 5–6; SCG10).
Further reduction on SCG10 protein level was observed after 12 h (Fig. 1C, lanes 3 and 7;
SCG10) and 24 h (Fig. 1C, lanes 4 and 8; SCG10). Previous report indicated that SCG10 is
associated with plasma membrane and Golgi (Lutjens et al., 2000; Maekawa et al., 2001).
Therefore, both supernatant (Fig. 1C, lanes 1–4) and pellet (Fig. 1C, lanes 5–8) fractions
were analyzed after Taxol treatment. In both fractions, we observed similar reduction on
SCG10 protein level (Fig. 1C; SCG10). However, western blot analysis using anti-stathmin
antibodies showed that Taxol does not affect stathmin protein levels (Fig. 1C; Stath). These
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results indicate that Taxol treatment of PC12 cells induced a decrease in the overall amount
of SCG10 proteins, but not related proteins such as stathmin.
Previous studies have demonstrated that microtubule-disrupting drugs, such as nocodazole
and colchicines, also induced cell death (Kim et al., 2002). Thus, PC12 cells were treated
with nocodazole [either 8.5 mM (Fig. 1D, lane 2) or 17 mM (Fig. 1D, lane 3)] for 4 h. After
treatment, cells were harvested and western blot analysis was performed. In contrast to what
was observed in Taxol-treated cells, acute nocodazole treatment did not induce a decrease in
SCG10 protein levels (Fig. 1D, lanes 2–3), despite the induction of apoptosis as illustrated
by the appearance of cleaved caspase-3 (Fig. 1D, compare lanes 1–3; Clev-Caspase3).
Importantly, these results indicate that the reduction in SCG10 protein level is not due to the
reported activation of apoptosis associated with both Taxol and nocodazole treatments
(Wang et al., 2000; Kim et al., 2002). Thus, Taxol treatment triggers a molecular mechanism
that leads to the degradation of the microtubule-destabilizing SCG10 protein in PC12 cells.
Proteasomal inhibition induced the expression of smaller SCG10 protein species
The ubiquitin–proteasome system (UPS) has been linked to rapid degradation of proteins in
response to environmental cues and insults (Kornitzer and Ciechanover, 2000).
Pharmacological studies were conducted in order to rule out a potential role of the UPS in
Taxol-induced SCG10 degradation. Undifferentiated PC12 cells were pre-treated for 3 h
with different concentrations of the proteasome inhibitor MG132 (Fig. 2A, lanes 3–5). After
pre-treatment, PC12 cells were incubated in presence of Taxol (10 μM; Fig. 2A, lanes 2–4)
for 24 h. Western blot analyses utilizing anti-ubiquitin antibody indicated the accumulation
of ubiquitinated proteins, confirming that the proteasome was efficiently inhibited (Figs. 2A
and 3B; Ub). The protein level of SCG10 protein was restored by all different MG132
concentrations. Interestingly, however, SCG10 proteins recovered were of smaller molecular
weight (~17 kDa) than the most prominent band detected in control samples (Fig. 2A,
compare lanes 1, 3, and 4; SCG10). The accumulation of this shorter SCG10 protein species
was also observed in samples from cells pre-treated with a different and more specific
proteasomal inhibitor, epoxomicin (Fig. 2B, lanes 3–4; SCG10). These results suggest that
proteasomal inhibition may block Taxol-induced SCG10 degradation. However, it is also
possible that this phenomenon is independent of the effect exerted by Taxol on PC12 cells.
In order to determine if the MG132- and epoxomicin-induced accumulation of the small
SCG10 protein species depends on Taxol treatment, we treated PC12 cells with MG132
alone for 24 h. As shown in Fig. 2A (lane 5), the smaller SCG10 protein species was also
detected in PC12 cells treated with MG132 alone. These results suggest that the small
SCG10 species induced by exposure of PC12 cells to both Taxol and proteasome inhibitor
was derived most likely from the major 17-kDa SCG10 species induced by proteasomal
inhibition. The 17-kDa species is about 3.6 kDa smaller than that deduced from the amino
acid sequences of intact SCG10 protein, raising the possibility that it may be a novel SCG10
isoform. Alternatively, it may represent a truncated SCG10 cleaved by activation of
proteases as a result of proteasomal inhibition. Regardless, it is questionable whether Taxol-
induced SCG10 degradation involves proteasomes. Therefore, these results indicate that
inhibition of the UPS may affect a different molecular mechanism than the one induced by
Taxol treatment, leading to the accumulation of an apparent lower molecular weight SCG10
protein.
Calpain-dependent SCG10 protein reduction upon Taxol treatment
It has been demonstrated that Taxol treatment induced the activation of calpain in
proliferating cells (Wang et al., 2004). Therefore, it is plausible that Taxol-induced
activation of calpain may mediate the degradation of SCG10 protein in PC12 cells. In order
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to determine the role that calpains may play in Taxol-induced SCG10 degradation,
undifferentiated PC12 cells were pre-treated with either inhibitor to caspase (Fig. 3B, lane 3)
or calpain (Fig. 3B, lane 4) for 3 h, followed by Taxol (10 μM) treatment for 24 h (Fig. 3B,
lanes 2–4). PC12 cells treated with either caspase inhibitor (Fig. 3A, lane 2) or calpain
inhibitor (Fig. 3A, lane 3) alone for 20 h were used as control. In contrast to that observed in
cells treated with either MG132 or epoxomicin (Fig. 2), no changes in SCG10 protein levels
were detected in cells treated with either vehicle control (Fig. 3A, lane 1) or in cells treated
with inhibitors either to caspase or calpain (Fig. 3A, compare lanes 1–3).
As expected, Taxol induced the activation of apoptosis as illustrated by the detection of
caspase-3 cleaved product (Fig. 3B, lane 2, Clev-Caspase3). This activation was efficiently
blocked by the caspase inhibitor Z-VAD-FMK (Fig. 3B, Clev-Caspase3, compare lanes 2
and 3). In spite of the inhibition of Taxol-induced caspase activation, SCG10 protein levels
were not restored (Fig. 3B, lane 3, SCG10). On the contrary, the calpain inhibitor
MDL-28170 did block Taxol-induced decrease in SCG10 protein level (Fig. 3B, lane 4,
SCG10). The accumulated SCG10 protein, however, has an apparent higher molecular
weight than SCG10 proteins found in control samples (Fig. 3B, compare lanes 1 and 4).
SCG10 plays a crucial role in neuronal development (Grenningloh et al., 2004). In order to
determine the effect of Taxol on SCG10 protein levels in differentiating cells, PC12 cells
were cultured in NGF-containing medium for three days. NGF-induced morphological
changes were monitored by light microscopy. Approximately 80% of PC12 cells showed
neurite extension after three days of incubation in NGF-containing medium (data not
shown), indicating that most cells were committed to differentiation. At this point, NGF-
differentiated PC12 cells were treated with different concentrations of Taxol (Fig. 3C, lane
2=1.0 μM and lane 3=10 μM) for 24 h. Consistently, SCG10 protein levels were drastically
reduced in cells cultured in presence of Taxol and not vehicle control (Fig. 3C, compare
lanes 1–3). Pre-treatment of NGF-differentiated PC12 cells with calpain inhibitor, followed
by treatment with Taxol (10 μM), blocked the observed reduction in SCG10 protein level
(Fig. 3C, lane 4, Cl). These results suggest that Taxol-induced SCG10 degradation, in both
undifferentiated and NGF-differentiating PC12 cells, is calpain dependent. Previous reports
indicated that MG132 could inhibit calpain protease activity. However, the accumulation of
two different SCG10 protein species after treatment with calpain (Figs. 3B and C) and
proteasome (Fig. 2) inhibitors indicates that there is not cross-inhibition due to lack of
specificity. Furthermore, MG132 provoked the accumulation of a lower molecular weight
SCG10 protein band in the absence of Taxol treatment (Fig. 2A, lane 5), whereas calpain
inhibitor MDL-28170 did not exert any effect on SCG10 in the absence of this treatment
(Fig. 3A, lane 3). Therefore, these results suggest that two distinct mechanisms may mediate
SCG10 protein degradation in PC12 cells.
Inhibition of known SCG10 kinases did not block Taxol-induced SCG10 degradation
Immunoblotting analysis of control samples, utilizing anti-SCG10 antibodies, showed three
major protein bands (Fig. 4A, lane 1, SCG10). Previous studies demonstrated that the level
of phosphorylation affects the gel electrophoresis mobility of SCG10 proteins (Antonsson et
al., 1998). Therefore, it is reasonable to suggest that the SCG10 protein-banding pattern
observed upon Taxol treatment could represent different phosphorylation states (Fig. 4A,
lane 1; SCG10). The level of this form of SCG10 increased substantially upon calpain
inhibitor treatment (Figs. 3B and C). Consequently, these results suggest that
hyperphosphorylation of SCG10 protein may precede its degradation and kinases known to
phosphorylate SCG10, such as protein kinases A (PKA), mitogen-activated protein kinase
(MAPK), or CDK5, may be involved in Taxol-induced SCG10 degradation. This possibility
was tested by pre-treatment of undifferentiated PC12 cells with either PKA (H89), MAPK
(PD98059), or CDK5 (Roscovitine) inhibitor prior to Taxol treatment for 24 h (Fig. 4A,
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lanes 3–5). In addition, these inhibitors were used in different combinations to rule out any
concurrent contribution of these kinases (Fig. 4A, lanes 6–9). Western blot analyses of
samples collected from different treatments indicated that none of the kinase inhibitors
restore the SCG10 protein level after Taxol treatment (Fig. 3D, compare lane 1 with lanes 3–
9). Interestingly, however, an anti-SCG10 antibody immunoreactive band corresponding to
the second SCG10 species (Fig. 4A, lanes 5 and 7–9, asterisk) was observed when CDK5
inhibitor was used. However, CDK5 inhibitor did not restore SCG10 protein to control
levels (Fig. 4A, compare lanes 1 and 9). These results indicate that kinases implicate in
SCG10 phosphorylation are not involved in Taxol-induced SCG10 degradation.
Alternatively, SCG10 phosphorylation may not be a regulatory factor in the molecular
mechanism leading to its degradation.
Overexpression of Tau protein induced calpain-dependent SCG10 degradation
Recently, it has been shown that suppression of tau expression makes cells more sensitive to
Taxol treatment (Rouzier et al., 2005). Furthermore, previous reports suggested that tau and
Taxol compete for the same binding site on microtubules to induce their stabilization (Kar et
al., 2003; Samsonov et al., 2004). Thus, the observed Taxol-induced SCG10 degradation
could be also triggered by microtubule stabilization due to overexpression of tau proteins.
This possibility was tested by using neuroblastoma cells expressing human tau (4R0N)
protein under the control of the Tet-Off system (Ko et al., 2005; see Materials and methods).
As previously reported (Ko et al., 2005), the level of tau expression corresponded inversely
to the concentration of tetracycline in the culturing medium (Fig. 5A, lanes 1–4; Tau) and
tau overexpression led to microtubule bundling. The highest tau expression was detected in
protein extract from cells cultured in medium containing 1 ng/mL of tetracycline after seven
days (Fig. 5A, lane 4; Tau). Moreover, very little exogenous tau were detected in cells
maintained in media containing 100 ng/mL or higher concentrations (Fig. 5A, lane 3; Tau).
Interestingly, the overexpression of tau proteins induced a reduction in SCG10 protein level
comparable to that observed in Taxol-treated cells (Fig. 5A, lanes 1–4; SCG10). The
induction of tau expression, with 10 ng/mL or 1 ng/mL, induced SCG10 degradation (Fig.
5A, compare lanes 3–4). The result indicates that increase tau expression lead to induction
of SCG10 protein degradation.
In PC12 cells, Taxol-induced decrease in SCG10 protein level is calpain-dependent (Fig. 3).
Therefore, in order to establish a mechanistic correlation between Taxol treatment and tau
overexpression, M1C neuroblastoma cells were pre-treated with either MG132 (Fig. 5B,
lanes 3–4) or calpain (Fig. 5B, lane 5) inhibitor followed by induction of tau overexpression
(Tet= 1 ng/mL) for 2 days. Consistently, overexpression of tau proteins induced the
elimination of SCG10 proteins (Fig. 5B, compare lanes 1 and 2; SCG10). This effect was
not blocked by pre-treatment with different concentrations of the proteasomal inhibitor
MG132 (Fig. 5B, lanes 3–4; SCG10), despite the fact of an increase accumulation of
ubiquitinated proteins (Fig. 5B, lanes 3–4; Ub). Interestingly, however, MG132 did also
increase the accumulation of tau proteins in comparison to untreated cells (Fig. 5B, compare
lanes 2–4; Tau). This MG132-induced accumulation of tau proteins is under investigation
(to be published elsewhere). On the other hand, pre-treatment of neuroblastoma cells with
calpain inhibitor blocked the reduction of SCG10 induced by tau overexpression (Fig. 5B,
compare lanes 2 and 5; SCG10). This finding indicates that, in response to tau
overexpression, SCG10 is degraded in a cal-pain-dependent manner. Consistently with what
was observed in PC12 cells, Taxol treatment of M1C cells without tau induction (Fig. 5C,
lane 2; SCG10 and Tau) also resulted in SCG10 degradation (Fig. 5C, compare lanes 1and
2). As control, non-tau transfected M1C neuroblastoma cells (Fig. 5C, lanes 3–4) were
treated with Taxol (Fig. 5C, lane 4) to corroborate that the observed reduction in SCG10
protein was not due to overexpression of tau proteins. As expected, Taxol treatment induced
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SCG10 protein degradation in these founder M1C neuroblastoma cells (Fig. 5C, compare
lanes 3 and 4). Collectively, these results indicate that both Taxol treatment and tau
overexpression may activate equivalent signaling cascades that lead to calpain activation and
SCG10 protein degradation.
Discussion
Microtubule dynamic instability plays a crucial role during neuronal differentiation. This
process requires the biological function of microtubule-stabilizing and -destabilizing
proteins. The expression of the microtubule-destabilizing protein SCG10 increases during
neuronal differentiation (Grenningloh et al., 2004). In mature neurons and adult brains, the
amount of SCG10 protein is reduced (Grenningloh et al., 2004). However, previous reports
demonstrated a transient increase in the expression of SCG10 after induction of long-term
potentiation in the rat hippocampal Schaffer–collateral CA1 pathway and during axonal
regeneration (Peng et al., 2003). In contrast, the expression of the microtubule-stabilizing
protein tau is constant during development and adulthood (Buèe et al., 2000). Collectively,
these findings indicate that there may be a molecular mechanism that regulates the function
and expression of these functional diverse proteins.
Here we describe the degradation of the microtubule-destabilizing SCG10 protein triggered
by overexpression of the microtubule-stabilizing protein tau or treatment with the anti-
mitotic drug Taxol, which is blocked by the calpain inhibitor MDL-28170. In
undifferentiated and differentiated PC12 cells, Taxol treatment induced a rapid reduction in
the SCG10 protein level that could be blocked by calpain inhibitors (Figs. 1 and 2). Calpain
inhibition induced the formation of higher molecular weight SCG10 species (Fig. 3). This
SCG10 higher molecular weight species may represent hyperphosphorylated SCG10,
suggesting that phosphorylation may precede its degradation. However, pharmacological
inhibition of kinases, known to phosphorylate SCG10, did not block the reduction of SCG10
exerted by Taxol treatment (Fig. 4). Importantly, both over-expression of tau proteins and
Taxol treatment in neuroblastoma cells induced reduction of SCG10 protein level (Fig. 5).
This effect was also blocked by pre-treatment with calpain inhibitor, indicating that
comparable molecular mechanisms mediate Taxol-induced SCG10 degradation in both rat
PC12 and human neuroblastoma cells. Taken together, these results suggest that microtubule
stabilization may activate a cellular response to down-regulate the function of the
microtubule-destabilizing SCG10 protein that is blocked by the calpain inhibitor
MDL-28170.
Treatment of PC12 cells with proteasome inhibitors induced neurite outgrowth and the
accumulation of a small SCG10 species. Pre-treatment of PC12 cells with both calpain and
proteasomal inhibitors followed by Taxol treatment promoted the accumulation of this
SCG10 species (data not shown). This result indicates that the effect exerted by proteasomal
inhibition on the accumulation of the SCG10 shorter form is independent of the Taxol-
activated pathway that leads to calpain-dependent degradation of SCG10 proteins. The
expression of this novel SCG10 species could be linked to the process of neurite outgrowth
induced by proteasomal inhibition. However, further experiments are needed in order to
understand the molecular properties of this novel SCG10 protein species and its role in
MG132-induced neurite outgrowth.
The biological function of calpains has been shown to play an important role in cell
development, cell motility, growth cone motility and guidance, learning, and memory,
among other cellular processes (Croall and DeMartino, 1991; Sato and Kawashima, 2001).
Additionally, abnormal activation of calpains has been associated with the development of
different diseases, including AD and Type-II diabetes mellitus (Zatz and Startling, 2005).
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Therefore, appropriate activation and function of calpains are essential for cellular survival
and, consequently, prevention of diseases. Interestingly, Wang et al. (2004) recently
reported that inhibition of calpain protects against peripheral neuropathy commonly
observed in patients treated with the antiancer drug Taxol (paclitaxel). In this study,
inhibition of calpain activity was shown to prevent axonal degeneration and neuropathy in
mice treated with Taxol (Wang et al., 2004). Therefore, it is reasonable to predict that
unregulated calpain-dependent degradation of SCG10 may affect neuronal polarity and
transmission.
We hypothesize that the stabilization of microtubules, by means of either Taxol treatment or
increase expression of tau proteins, activates a signaling cascade to down-regulate the
function of the microtubule disrupting SCG10 protein. Alternatively, overexpressed tau
proteins and Taxol molecules may prevent the binding of SCG10 protein to tubulin
molecules, rendering it susceptible to degradation. This mechanism may also coordinate the
activity of microtubule-stabilizing and -disrupting proteins during neuronal development and
function. In mature neurons, particularly in those involved in learning and memory, this
putative pathway may become inactivated during induction of long-term potentiation to
allow the expression of SCG10 and transient regulation of microtubule dynamics required
for neuronal plasticity. Consequently, this novel molecular mechanism may play a central
role in coordinating cytoskeleton changes required during neuronal development and
function.
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Fig. 1.
Taxol treatment of undifferentiated PC12 cells induced reduction in SCG10 protein level.
(A) Undifferentiated PC12 cells were treated with the indicated Taxol concentrations for 24
h. Control samples (C; lanes 1–3) were treated with vehicle control (40 μL ethanol) for the
same period of time. The cells were harvested and equal protein concentration (10 μg) was
loaded on a 12.5% SDS–PAGE. Western blot analysis was performed utilizing anti-SCG10-
BL antibody. As loading control, the membrane was re-probed with anti-tubulin antibody.
(B) Quantification of SCG10, in each treatment condition, indicated a reduction of up to
90% in 10 μM Taxol (see Materials and methods). Bar per sample set represent the mean of
three independent experiments and the error bar shows the standard error [σ/(√n)] (*p
value<0.0001). (C) Time course experiment using 10 μM Taxol was carried out (lanes 2 and
6=4 h, lanes 3 and 7=12 h, and lanes 4 and 8=24 h). Reduction in SCG10 protein level was
observed as early as 4 h in both supernatant (Sup-lanes 2–4) and Pellet (lanes 6–8) fractions.
In contrast, the protein level of stathmin (Stath) was unchanged. Tubulin was used as a
loading control. (D) Nocodazole does not affect SCG10 protein level. Undifferentiated PC12
cells were treated with the microtubule-destabilizing drug nocodazole (Ncd; lanes 2=8.5
mM and lane 3=17 mM) for 4 h. As control (C; lane 1), cells were treated with DMSO (25
μL). Western blot analysis demonstrated that Ncd treatment of PC12 cells does not affect
SCG10 protein levels, despite the activation of caspases (Clev-Caspase3). Actin was used as
a loading control. The arrow in panels A and B indicates slow migrating SCG10 protein
induced after Taxol treatment. The asterisk in panel B indicates the ~17-kDa SCG10
species.
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Fig. 2.
Proteasome inhibition induced the expression of shorter SCG10 protein species. (A)
Undifferentiated PC12 cells were treated with Taxol (10 μM) in the absence (lane 2) or
presence (lanes 2–4) of the indicated concentrations of the proteasome inhibitor MG132. As
control (lane 1), cells were treated with vehicle control [ethanol (40 μL) and DMSO (20
μL)]. Undifferentiated PC12 cells were also treated with MG132 alone (lane 5). (B) PC12
cells were pre-treated with a different proteasomal inhibitor, epoxomicin (lanes 3–4), at the
indicated concentrations followed by Taxol treatment. As control, PC12 cells were treated
with vehicle control (lane 1) or Taxol alone (lane 2). In panels A and B, the antibodies anti-
SCG10-GL (SCG10), anti-ubiquitin P4D1 (Ub), and anti-tubulin (Tub) were used for
western blot analyses. The results indicated that proteasome inhibition affects SCG10
expression independent of the effect exerted by Taxol treatment.
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Fig. 3.
Taxol-induced and calpain-dependent SCG10 degradation. In order to determine the role of
caspases and calpain activation on the reduction in SCG10 protein level upon Taxol
treatment (10 μM), undifferentiated PC12 cells were pre-treated with either caspase (Cs; Z-
VAD-FMK; 40 μM) or calpain (Cl; MDL-28170; 10 μM) inhibitor for 3 h. (A)
Undifferentiated PC12 cells were treated with Cs (lane 2) or Cl (lane 3) for 24 h to
determine the effect that caspases and calpain exerts on SCG10 independently of Taxol
treatment. As control, PC12 cells were treated with DMSO (lane 1). Western blot analysis of
the samples collected was performed utilizing SCG10-BL antibodies. Tubulin
immunoblotting was performed as loading control. The result indicates that treatment with
Cs or Cl did not affect SCG10 protein levels. (B) Undifferentiated PC12 cells were pre-
treated with either Cs (40 μM, lane 3) or Cl (10 μM, lane 4) for 3 h. After pre-treatment,
Taxol (10 μM; lanes 2–4) was added to the medium for 24 h. In lane 1, we loaded protein
lysate from PC12 cells treated with vehicle control (ethanol and DMSO). Western blot
analyses were performed, employing the indicated antibodies. The result indicates that
SCG10 protein is accumulated after Taxol treatment only if undifferentiated PC12 cells
were pre-treated with Cl. Actin was used as a loading control. (C) NGF-differentiated PC12
cells were treated for 24 h with either 1.0 μM (lane 2) or 10 μM (lanes 3–4) Taxol. As
control, differentiated PC12 cells were treated with ethanol and DMSO (lane 1).
Consistently, Taxol treatment induced SCG10 protein degradation. Pre-treatment of
differentiated PC12 cells with Cl (10 μM, lane 4) for 3 h, followed by Taxol (10 μM)
treatment for 24 h, blocked the observed Taxol-induced SCG10 degradation (lane 4).
Tubulin immunoblotting was used as loading control. The arrow in panels A and B indicates
the slow migrating SCG10 protein species recovered after Cl treatment.
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Fig. 4.
Inhibition of known SCG10 kinases did not blocked Taxol-induced SCG10 degradation. (A)
Undifferentiated PC12 cells were pre-treated with PKA (20 μM; H89; lanes 3, 6–7 and 9),
MEK (30 μM; PD; PD98059, lanes 4, 6, and 8–9), and CDK5 (5 μM; Ros; Roscovitine,
lanes 5 and 7–9) inhibitors for 3 h. Then, Taxol (10 μM) was added to the medium. Cells
were harvested after 24 h of incubation with the indicated drugs. The SCG10 protein levels
were accessed by western blot analysis utilizing anti-SCG10-BR antibodies (SCG10).
Tubulin was used as a loading control (Tub). The arrow marks the higher molecular weight
SCG10 species induced upon Taxol treatment. The asterisk indicates the location of the
SCG10 protein shift upon Ros treatment.
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Fig. 5.
Overexpression of Tau protein induced calpain-dependent SCG10 degradation. (A) The
expression of human tau in M1C cells was induced by decreasing concentration of
tetracycline (Tet, lanes 2–4). Protein extract from neuroblastoma cells under uninducible
conditions was used as control (lane 1). The cells were harvested after 7 days of incubation.
The steady-state level of SCG10 and tau proteins was accessed by western blot analysis,
employing the antibodies anti-SCG10-BR (SCG10) and human-specific anti-tau (WKS44).
(B) M1C cells were pre-treated with either MG132 (lanes 3–4, at the indicated
concentration) or calpain (10 μM; Cal; lane 5) inhibitor for 3 h prior to the induction of tau
expression for 2 days. The protein extracts from neuroblastoma cells without (lane 1) or with
(lane 2) induction of tau overexpression were used as control. Western blot analysis was
conducted utilizing the indicated antibodies. Anti-ubiquitin (Ub) immunoblotting was used
to determine the accumulation of ubiquitinated proteins after MG132 treatment. (C) M1C
cells without tau induction (NI, lanes 1–2) or non-tau transfected neuroblastoma cells (NT,
lanes 3–4) were treated with Taxol (10 μM; lanes 2 and 4) for 24 h. Western blot analysis
utilizing anti-SCG10BR (SCG10) or anti-Tau (Tau) antibodies was used to determine the
level of these proteins. In panels A,–C, anti-tubulin (Tub) immunoblotting was used as a
loading control.
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